Category: catalyst-ligand

71071-46-0, Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A 1-liter, creased, 4-necked round bottom Pyrex flask equipped with mechanical stirrer, 250-milliliter (ml) addition funnel, temperature probe, heating mantle, and water-cooled total reflux condenser was used. The flask was initially charged with 200 grams (1.08 mole) of ADMA-10 (decyldimethylamine, available from Albemarle Corporation, Baton Rouge, LA), and 239 grams (1.08 mole) decyl bromide was placed in the addition funnel. The stirrer was turned on and the reactor was heated to 65C. The decyl bromide was added dropwise to the ADMA-10 as the temperature of the reactor was allowed to rise from 65C to 142C. The addition funnel was then charged with 110 grams of methanol, and the methanol was added dropwise to the solution as the temperature of the reactor was allowed to fall to 90C. After the entire volume of the methanol was added to the reaction mixture, the heat and stirring were ceased and the intermediate quaternary ammonium (quat-Br) solution was allowed to cool., 71071-46-0

71071-46-0 Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate 326419, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Patent; ALBEMARLE CORPORATION; WO2005/97729; (2005); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: (R)-LiPr (50mg, 0.17mmol) was dissolved in acetonitrile (15cm3). Zinc(II) tetrafluoroborate hydrate (20mg, 0.083mmol) was then added and the solution stirred at room temperature for one hour. A large excess of diethyl ether was added and the resultant precipitate was isolated by vacuum filtration leaving a white powder. Single crystals suitable for X-ray diffraction analysis were grown by vapour diffusion of diethyl ether into a concentrated solution of the product in acetonitrile. Yield: 0.054g, 78%., 118949-61-4

The synthetic route of 118949-61-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, General procedure: A solution of cis-RuII(bpz)2Cl2 (100 mg, 0.205 mmol) and AgNO3 (77 mg, 0.453 mol) in water (25 mL) was heated at reflux for 48 h. After cooling to room temperature, the mixture was filtered through Celite to remove AgCl, and the filtrate was evaporated to dryness. The residue was dissolved in DMF (15 mL) and the solution purged with argon for 15 min. 4,4?-bis(trifluoromethyl)-2,2?-bipyridyl (121 mg, 0.414 mmol) was added and the mixture heated at 100 °C for 24 h under argon. After cooling to room temperature, the solution was evaporated under vacuum to a small volume and diethyl ether (150 mL) added. The precipitate was filtered off and dissolved in a minimum of cold water to which solid NH4PF6 was added. The solid was filtered off and purified by column chromatography as for 1 to give an orange solid. Yield: 73 mg (35percent).

The synthetic route of 71071-46-0 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Coe, Benjamin J.; Peers, Martyn K.; Scrutton, Nigel S.; Polyhedron; vol. 96; (2015); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937., 22348-32-9

As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937., 22348-32-9

As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.71071-46-0,Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate,as a common compound, the synthetic route is as follows.

71071-46-0, A solution of compound 9 (200mg, 0.39mmol), dimethyl 2,2?-bipyridine-4,4?-dicarboxylate (212mg, 0.78mmol), and potassium hexafluorophosphate (108mg, 0.585mmol) in dry 1,2-dichloroethane (20mL) was stirred at 40°C for 24h. The reaction mixture was concentrated under reduced pressure and the crude product was purified by column chromatography using ethyl acetate/ dichloromethane (1:1) to give compound 10 as a dark red solid (198mg, 50percent). 1H NMR (300MHz, CDCl3): delta 8.88 (s, 1H), 8.83 (s, 1H), 8.75 (s, 2H), 8.27 (d, J=6Hz, 1H), 8.02 (dd, J=1.5Hz, 1.5Hz, 1H), 7.80 (d, J=5.4Hz, 1H), 7.84 (d, J=6.3Hz, 1H), 7.76(dd, J=1.5Hz, 1.5Hz, 1H), 7.69 (dd, J=1.5Hz, 1.5Hz, 1H), 7.59?7.64 (m, 5H), 7.30(d, J=5.4Hz, 1H), 7.01?7.16 (m, 1H), 6.89 (q, J=5.4Hz, 1H), 6.52 (q, J=7.8Hz, 1H), 4.00 (s, 3H), 3.99 (s, 3H), 3.98 (s, 3H), 3.96 (s, 3H); 13C NMR (125MHz, CDCl3): delta 181.4, 164.3, 164.3, 164.1, 163.9, 162.1, 159.5 (d, JCF=252.1Hz), 157.9, 157.3, 156.6, 156.4, 155.4, 151.6, 150.7, 150.4, 145.6, 138.4, 137.2, 136.3, 135.8, 135.7, 135.4, 135.2, 128.1, 126.2, 126.1, 125.8, 125.7, 125.1, 122.8, 122.7, 122.1, 121.9, 121.6, 120.0, 119.0, 109.5 (d, JCF=22.7Hz), 53.4, 53.3, 53.2; HRMS (FAB): calcd. for C41H31FN5O8SRu [M+] 874.0921, found 874.0923.

71071-46-0 Dimethyl [2,2′-bipyridine]-4,4′-dicarboxylate 326419, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Li, Chung-Yen; Su, Chaochin; Wang, Hsiou-Hsuan; Kumaresan, Prabakaran; Hsu, Chia-Hsuan; Lee, I-Ting; Chang, Wei-Chun; Tingare, Yogesh S.; Li, Ting-Yu; Lin, Chia-Feng; Li, Wen-Ren; Dyes and Pigments; vol. 100; 1; (2014); p. 57 – 65;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1148-79-4,2,2′:6′,2”-Terpyridine,as a common compound, the synthetic route is as follows.

Solid [Co(H2O)6](ClO4)2 (10.0 mg, 21.8 lmol) was placed at thebottom of a 4.0 cm3 test tube with 0.50 cm3 of dmso. Then the tubewas slowly filled with 2.50 cm3 of a dmso?CH3OH mixture (1:4 v/v)containing terpy (15.0 mg, 64.4 lmol). Finally, 1 (15.0 mg,9.01 lmol) dissolved in 0.50 cm3 of CH3OH was placed on the topand the tube covered with parafilm. X-ray quality deep browncrystals of 2 were grown in the text tube by slow diffusion at roomtemperature during 25 days. Yield: 3.20 mg (1.30 lmol, 29percent). X-rayabsorption microanalysis for 2: 3:2 Co/Nb molar ratio. Elementalanalysis for C105H86N18O33Co3Nb2 (2490.52 g mol1) ? Exp. (Calc.):percentC 51.55 (50.94), percentH 3.02 (3.18), percentN 10.49 (10.32), percentCo 7.50 (7.30)percent.IR (KBr disk/cm1): 3475 [m(O?H)], 3062 and 2930 [m(C?H)], 1715and 1687 [mas(CO)], 1641 [m(CN)], 1470 and 1448 [m(CC)],1401 [ms(CO)], 905 [m(NbO] and 421 [m(CoAN)].

1148-79-4, The synthetic route of 1148-79-4 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Oliveira, Willian X.C.; Pereira, Cynthia L.M.; Pinheiro, Carlos B.; Krambrock, Klaus; Grancha, Thais; Moliner, Nicolas; Lloret, Francesc; Julve, Miguel; Polyhedron; vol. 117; (2016); p. 710 – 717;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.128249-70-7,2,6-Bis((R)-4-phenyl-4,5-dihydrooxazol-2-yl)pyridine,as a common compound, the synthetic route is as follows.

Cobalt(II) tetrafluoroborate hydrate (25mg, 0.0675mmol) was added to a solution of (R)-LPh (50mg, 0.135mmol) in acetonitrile (15cm3). The resultant orange solution was stirred at room temperature for one hour. The product was precipitated using an excess of diethyl ether and the precipitate was collected by vacuum filtration, leaving an orange powder. A vapour diffusion of diethyl ether into a concentrated solution of the complex in acetonitrile gave orange crystals suitable for X-ray diffraction. Yield: 0.056g, 84%. Elemental microanalysis: found C, 56.6; H, 3.81; N, 8.53%: calcd for C46H38B2CoF8N6O4 C, 56.9; H, 3.94; N, 8.65%. 1H NMR (CD3CN): delta 2.7 (8H, Ph H2/6), 3.0 (4H, Ph H4), 7.7 (8H, Ph H3/5), 20.0 and 36.8 (both 4H, Ox H5), 40.5 (4H, Py H3/5), 84.7 (4H, Ox H4). No peak from the Py H4 proton environment was observed, which may be obscured by the CHD2CN solvent peak., 128249-70-7

The synthetic route of 128249-70-7 has been constantly updated, and we look forward to future research findings.

Reference：
Article; Burrows, Kay E.; Kulmaczewski, Rafal; Cespedes, Oscar; Barrett, Simon A.; Halcrow, Malcolm A.; Polyhedron; vol. 149; (2018); p. 134 – 141;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

118949-61-4, 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of [Ru(p-cymene)Cl2]2 (306 mg, 0.5 mmol) and pybox-ip (301 mg, 1.0 mmol) in MeOH (7.0 mL) wasadded a solution of disodium pyridine-2,6-dicarboxylate (1.0 mmol) in MeOH-H2O (2:1 v/v, 15 mL) under argonatmosphere. The mixture was stirred at 60 oC for 1 h. The product was extracted with CH2Cl2 (40 mL). The combinedorganic layers were concentrated and the residue was purified by silica gel column chromatography withCH2Cl2MeOH (50:1 v/v) to give A* as a dark greenish-violet solid (444.0 mg, 0.78 mmol) in 78% yield.

118949-61-4, 118949-61-4 2,6-Bis((S)-4-isopropyl-4,5-dihydrooxazol-2-yl)pyridine 688211, acatalyst-ligand compound, is more and more widely used in various fields.

Reference：
Article; Fakhruddin, Ahmad; Abu-Elfotoh, Abdel-Moneim; Shibatomi, Kazutaka; Iwasa, Seiji; Letters in Organic Chemistry; vol. 15; 3; (2018); p. 196 – 205;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.22348-32-9,(R)-Diphenyl(pyrrolidin-2-yl)methanol,as a common compound, the synthetic route is as follows.

To (S)-diphenylprolinol (4.00 g, 15.8 mmol, 1.00 equiv) in CH2-Cl2 (40 mL) was added imidazole (3.22 g, 47.4 mmol, 3.00 equiv)at 0 C. TMSCl (5.00 mL, 39.5 mmol, 2.50 equiv) was added dropwiseand the reaction was stirred for 12 h at rt. MTBE (100 mL)was added to the reaction and the mixture was filtered. Theorganic phase was washed with H2O (50 mL) and saturated aqueousNaCl (2 50 mL), dried over MgSO4, filtered and concentratedunder reduced pressure to a colorless oil 11 (5.00 g, 15.3 mmol,97%). 1H NMR (400 MHz, CDCl3) d 7.54-7.46 (m, 2H), 7.42-7.36(m, 2H), 7.35-7.20 (m, 6H), 4.07 (t, J = 7.4 Hz, 1H), 2.98-2.75 (m,2H), 1.84-1.72 (m, 1H), 1.68-1.55 (m, 3H), 1.48-1.37 (m, 1H),0.06 (s, 9H) ppm. 13C NMR (101 MHz, CDCl3) d 146.83, 145.78,128.44, 127.61, 127.57, 127.53, 126.90, 126.73, 83.17, 65.42,47.16, 27.51, 25.06, 2.20 ppm. HR-MS (ESI): calculated for (C20H28-NOSi) [M+H]+: 326.1935, found: 326.1937.

22348-32-9, As the paragraph descriping shows that 22348-32-9 is playing an increasingly important role.

Reference：
Article; Murar, Claudia E.; Harmand, Thibault J.; Bode, Jeffrey W.; Bioorganic and Medicinal Chemistry; vol. 25; 18; (2017); p. 4996 – 5001;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI